#DYK that #KRAS mutations drive 25% of all solid tumors? Our lead investigational candidate, ELI-002, is a lymph-node targeted mutant mKRAS #CancerVaccine designed to target these KRAS mutations. Learn more about ELI-002 and our other candidates here: https://lnkd.in/grzjhvxa
Elicio Therapeutics
Biotechnology Research
Boston, Massachusetts 4,357 followers
Orchestrating the immune response to defeat cancer & infectious diseases
About us
Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing a pipeline of novel lymph node-targeted immunotherapies for the treatment of some of the most aggressive cancers. By combining expertise in immunology and immunotherapy, Elicio is harnessing the natural power of the immune system with the Amphiphile (“AMP”) technology, which allows for therapeutic payloads to be delivered directly to the lymph nodes, with the goal of enhancing the immune system’s cancer-fighting capabilities. By targeting cancer immunotherapies to the core of the immune response, AMP aims to optimize the lymph nodes’ natural ability to educate, activate and amplify cancer-specific T cells, which are essential for recognizing and eliminating tumor cells. Engineered to synchronize immunity in these highly potent sites, AMP is built to enhance the magnitude, potency, quality and durability of the immune response to drive antitumor activity. The Company’s R&D pipeline includes off-the-shelf therapeutic cancer vaccines ELI-002, (targeting mKRAS-driven cancers) as well as ELI-007 and ELI-008 (targeting BRAF-driven cancers and p53 hotspot mutations, respectively). For more information, please visit www.elicio.com.
- Website
-
http://www.elicio.com
External link for Elicio Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Boston, Massachusetts
- Type
- Public Company
Locations
-
Primary
Get directions
451 D Street
501
Boston, Massachusetts 02210, US
Employees at Elicio Therapeutics
Updates
-
Elicio is in Chicago for the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting! We presented our poster on the preliminary data from our ongoing AMPLIFY-7P Phase 1 study. This data is a great way to gleam our latest work in #CancerVaccines. To learn more about the data and our pipeline, see here: https://lnkd.in/e5-r4myZ #ASCO24
-
Join us in celebrating the talent that makes Elicio thrive! For our #EmployeeSpotlight this month, meet Alaina Ownbey, Elicio’s Controller! Alaina expertly manages all accounting-related and external reporting activities, driving excellence in our financial operations. We appreciate Alaina's passion and dedication to creating positive change in #ImmunoOncology.
-
-
Elicio is working to forge a new path for next-generation #CancerTreatments. Our AMP technology aims to optimize the lymph nodes' natural ability to educate, activate, and amplify cancer-specific T cells. Explore our technology here: https://lnkd.in/gxW9eegh
-
#DYK that the lymph nodes influence the magnitude and quality of every immune response? Our AMP technology is designed to harness the natural power of the immune system by delivering #Immunotherapies directly to the lymph nodes. Learn more here: https://lnkd.in/erfeGrHG
-
Check out our #ASCO24 poster presentation with preliminary data from the ongoing AMPLIFY-7P study of our off-the-shelf investigational therapeutic #CancerVaccine candidate. Learn more about our presence at American Society of Clinical Oncology (ASCO)'s Annual Meeting: https://lnkd.in/g3Sf8Q-S
Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting | Elicio Therapeutics
https://elicio.com
-
Elicio is excited to join the Oncology Innovation Forum in Chicago on May 31st. Don't miss our CSO, Peter DeMuth, Ph.D., as he participates in a panel discussion on recent therapeutic advancements in #Oncology. Learn more: https://lnkd.in/grkN55q2 #Sachs_OIF
-
-
Today we reported first quarter 2024 financial results including corporate and clinical updates. Read the full press release here: https://lnkd.in/eieuKf9x
-
May is #NationalCancerResearchAwarenessMonth. This month and every month, our exceptional team is committed to pushing the boundaries in #CancerVaccine development and advancing our vaccine candidates. Learn more about our current candidates here: https://lnkd.in/grzjhvxa
-
Join us at the 20th Annual PEGS Boston Summit featuring our CSO, Peter DeMuth, Ph.D., as he presents the most recently reported results from our Phase 1 lymph node-targeting vaccine study targeting mutant KRAS. #PEGSummit Find more details here: https://lnkd.in/gEmUfUzy
PEGS Summit | Elicio Therapeutics
https://elicio.com